Chlamydia pneumoniae and cardiovascular disease: An evolutionary perspective on infectious causation and antibiotic treatment

Journal of Infectious Diseases

Volumn 181, Issue 6 SUPPL. 3, 2000, Pages

  Ewald, Paul W ^a   Cochran, Gregory M ^b  

^a AMHERST COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; EVOLUTION; GENETIC PREDISPOSITION; HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0034089724     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315602     Document Type: Conference Paper

References (45)

1. 1. Cochran GM, Ewald PW, Cochran KD. Infectious causation of disease: an evolutionary perspective. Perspect Biol Med 2000;43 (in press).
2. 2. Vogel F, Motulsky AG. Human genetics, 3rd ed. Berlin: Springer Verlag, 1997.
3. 3. Wolinsky H. Atherosclerosis. In: Beeson PB, McDermott W, Wyngaarden JB, eds. Cecil textbook of medicine, 15th ed. Philadelphia: Saunders, 1979: 1218-23.
4. 4. Ewald PW. Evolution of infectious disease. New York: Oxford University Press, 1994.
5. 5. Nieto FJ. Infections and atherosclerosis: new clues from an old hypothesis? Am J Epidemiol 1998;148:937-48.
6. 6. Ji Y, Urakami K, Adachi Y, Maeda M, Isoe K, Nakashima K. Apolipoprotein E polymorphism in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease. Dement Geriatr Cogn Disord 1998;9:243-5.
7. 7. Urakami K, Adachi Y, Wakutani Y, et al. Epidemiologic and genetic studies of dementia of the Alzheimer type in Japan. Dement Geriatr Cogn Disord 1998;9:294-8.
8. 8. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE epsilon 4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;67:203-5.
9. 9. Ilveskoski E, Perola M, Lehtimaki T, et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men. An autopsy study. Circulation 1999;100:608-13.
10. 10. Mahley RW, Huang YD. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999;10:207-17.
11. 11. Abel L, Dessein AJ. The impact of host genetics on susceptibility to human infectious diseases. Curr Opin Immunol 1997;9:509-16.
12. 12. Gérard HC, Wang GF, Balin BJ, Schumacher HR, Hudson AP. Frequency of apolipoprotein E (APOE) allele types in patients with Chlamydia-associated arthritis and other arthritides. Microb Pathog 1999;26:35-43.
13. 13. Hamilton WD. Seething genetics of health and the evolution of sex. In: Osawa S, Honjo T, eds. Evolution of life, fossils, molecules, and culture. Berlin: Springer, 1991:229-51.
14. 14. Hamilton WD. Haploid dynamical polymorphism in a host with matching parasites: effects of mutation/subdivision, linkage, and patterns of selection. J Hered 1993;84:328-38.
15. 15. Romero I, Jorgensen P, Bolwig G, et al. A presenilin-I ThrII6Asn substitution in a family with early-onset Alzheimer's disease. Neuroreport 1999;10:2255-60.
16. 16. Itoh Y, Yamada M, Sodeyama N, et al. Atherosclerosis is not implicated in association of APOE epsilon 4 with AD. Neurology 1999;53:236-7.
17. 17. Nochlin D, Shaw CM, Campbell LA, Kuo CC. Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease. Neurology 1999;53: 1888.
18. 18. Gilden DH. Chlamydia: a role for multiple sclerosis or more confusion? Ann Neurol 1999;46:4-5.
19. 19. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 1998;50:571-2.
20. 20. Boudreau DA, Scheer WD, Malcom GT, Mulvad G, Pedersen HS, Jul E. Apolipoprotein E and atherosclerosis in Greenland Inuit. Atherosclerosis 1999;145:207-19.
21. 21. Loktionov A, Vorster H, O'Neill IK, et al. Apolipoprotein E and methylenetetrahydrofolate reductase genetic polymorphisms in relation to other risk factors for cardiovascular disease in UK Caucasians and black South Africans. Atherosclerosis 1999;145:125-35.
22. 22. Saikku P. Chronic Chlamydia pneumonia infections. In: Allegra L, Blasi F, eds. Chlamydia pneumoniae infection. Berlin: Springer, 1995.
23. 23. Kontula K, Vuorio A, Turtola H, Saikku P. Association of seropositivity for Chlamydia pneumoniae and coronary artery disease in heterozygous' familial hypercholesterolaemia. Lancet 1999;354:46-7.
24. 24. Berenson GS, Srinivasan SR, Bao WH, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998;338:1650-6.
25. 25. Zieske AW, Takei H, Fallon KB, Strong JP. Smoking and atherosclerosis in youth. Atherosclerosis 1999;144:403-8.
26. 26. von Hertzen LC. Chlamydia pneumoniae and its role in chronic obstructive pulmonary disease. Ann Med 1998;30:27-37.
27. 27. He J, Vupputuri T, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease. A meta-analysis of epidemiologic studies. N Engl J Med 1999;340:920-6.
28. 28. Bonita R, Duncan J, Truelsen T, Jackson RT, Beaglehole R. Passive smoking as well as active smoking increases the risk of acute stroke. Tob Control 1999;8:156-60.
29. 29. Bailar JC. Passive smoking, coronary heart disease, and meta-analysis. N Engl J Med 1999;340:958-9.
30. 30. Valkonen M, Kuusi T. Passive smoking induces atherogenic changes in low-density lipoprotein. Circulation 1998;97:2012-6.
31. 31. Takala AK, Clements DA. Socioeconomic risk factors for invasive Haemophilus influenzae type b disease. J Infect Dis 1992;165(suppl):S11-5.
32. 32. Vadheim CM, Greenberg DP, Bordenave N, et al. Risk factors for invasive Haemophilus influenzae type b in Los Angeles County children 18 60 months of age. Am J Epidemiol 1992;136:221-35.
33. 33. Arnold C, Makintube S, Istre GR. Day care attendance and other risk factors for invasive Haemophilus influenzae type b disease. Am J Epidemiol 1993;138:333-40.
34. 34. Leinonen M, Saikku P. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis. Am Heart J 1999;138:S504-6.
35. 35. Kalayoglu MV, Miranpuri GS, Golenbock DT, Byrne GI. Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect 1999;I:409-18.
36. 36. deValk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999;159:1542-8.
37. 37. Sullivan JL, Weinberg ED. Iron and the role of Chlamydia pneumoniae in heart disease [letter]. Emerg Infect Dis 1999;5:724-6.
38. 38. Grayston JT, Mordhorst CH, Bruu AL, Vene S, Wang SP. Community and hospital acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch Intern Med 1989;149:169-73.
39. 39. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992;15:757-63.
40. 40. Saikku P. The epidemiology and significance of Chlamydia pneumoniae. J Infect 1992;25:27-34.
41. 41. Einarsson S, Sigurdsson HK, Magnusdottir SD, Erlendsdottir H, Briem H, Gudmundsson S. Age specific prevalence of antibodies against Chlamydia pneumoniae in Iceland. Scand J Infect Dis 1994;26:393-7.
42. 42. Koivisto AL, Isoaho R, vonKertzen L, et al. Chlamydial antibodies in an elderly Finnish population. Scand J Infect Dis 1999;31:135-9.
43. 43. Wissler RW, Strong JP. Risk factors and progression of atherosclerosis in youth. Am J Pathol 1998;153:1023-33.
44. 44. Monno R, DiBitonto G, Marcuccio L, Valenza M, Marcuccio C. Antibodies to Chlamydia pneumoniae in healthy children from Bari, South Italy. Microbiol 1998;21:281-4.
45. 45. Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992;14:178-82.